First Time Loading...
H

Hillevax Inc
NASDAQ:HLVX

Watchlist Manager
Hillevax Inc
NASDAQ:HLVX
Watchlist
Price: 16.63 USD 6.47% Market Closed
Updated: Mar 29, 2024

Intrinsic Value

Hillevax Inc is a US-based company operating in Biotechnology industry. [ Read More ]

There is not enough data to reliably calculate the intrinsic value of HLVX.

Key Points:
HLVX Intrinsic Value
Base Case
Not Available
H
Base Case Scenario

Fundamental Analysis

Financials

Balance Sheet Decomposition
Hillevax Inc

Current Assets 310.7m
Cash & Short-Term Investments 303.5m
Other Current Assets 7.2m
Non-Current Assets 33.8m
PP&E 32.1m
Other Non-Current Assets 1.7m
Current Liabilities 29.3m
Accounts Payable 7.5m
Accrued Liabilities 21.8m
Non-Current Liabilities 49.6m
Long-Term Debt 25.2m
Other Non-Current Liabilities 24.4m
Efficiency

Earnings Waterfall
Hillevax Inc

Revenue
0 USD
Operating Expenses
-133.3m USD
Operating Income
-133.3m USD
Other Expenses
9.8m USD
Net Income
-123.6m USD

Free Cash Flow Analysis
Hillevax Inc

Last Value
3-Years Average
FCF Margin
Conversion Rate
History
Components
Chart
Table
What is Free Cash Flow?
Fundamental Scores

HLVX Profitability Score
Profitability Due Diligence

Hillevax Inc's profitability score is 41/100. The higher the profitability score, the more profitable the company is.

Exceptional 3-Year Average ROIC
Negative Free Cash Flow
Negative Operating Income
Negative Net Income
41/100
Profitability
Score

Hillevax Inc's profitability score is 41/100. The higher the profitability score, the more profitable the company is.

HLVX Solvency Score
Solvency Due Diligence

Hillevax Inc's solvency score is 66/100. The higher the solvency score, the more solvent the company is.

Short-Term Solvency
Long-Term Solvency
Negative Net Debt
Low D/E
66/100
Solvency
Score

Hillevax Inc's solvency score is 66/100. The higher the solvency score, the more solvent the company is.

Wall St
Price Targets

HLVX Price Targets Summary
Hillevax Inc

Wall Street analysts forecast HLVX stock price to rise over the next 12 months.

According to Wall Street analysts, the average 1-year price target for HLVX is 28.76 USD with a low forecast of 21.21 USD and a high forecast of 35.7 USD.

Lowest
Price Target
21.21 USD
28% Upside
Average
Price Target
28.76 USD
73% Upside
Highest
Price Target
35.7 USD
115% Upside
View Analyst Estimates
View Analyst Estimates

Competitive Landscape

Ownership

HLVX Insider Trading
Buy and sell transactions by insiders

Cumulative Transactions Amount
Period Sold Bought Net
3 Months
6 Months
9 Months
12 Months
Why is insider trading important?

Shareholder Return

HLVX Price
Hillevax Inc

1M 1M
-8%
6M 6M
+24%
1Y 1Y
+0%
3Y 3Y
-2%
5Y 5Y
-2%
10Y 10Y
-2%
Annual Price Range
16.63
52w Low
10.35
52w High
19.75
Price Metrics
Average Annual Return -11.18%
Standard Deviation of Annual Returns
N/A
Max Drawdown -57%
Shares Statistics
Market Capitalization 792.7m USD
Shares Outstanding 48 437 000
Percentage of Shares Shorted 1.42%

HLVX Return Decomposition
Main factors of price return

What is price return decomposition?

Company Profile

Hillevax Inc

Country

United States of America

Industry

Biotechnology

Market Cap

792.7m USD

Dividend Yield

0%

Description

Hillevax Inc is a US-based company operating in Biotechnology industry. The company is headquartered in Boston, Massachusetts. The company went IPO on 2022-04-29. HilleVax, Inc. is a clinical-stage biopharmaceutical company focused on developing and commercializing novel vaccines. The firm's program, HIL-214, is a virus-like particle (VLP) based vaccine candidate in development for the prevention of moderate-to-severe acute gastroenteritis (AGE) caused by norovirus infection. Norovirus is the most common cause of viral AGE worldwide and is characterized by symptoms, including diarrhea, vomiting, abdominal pain, nausea, and, sometimes, fever that may lead to clinically significant dehydration. The firm's HIL-214 is a bivalent (containing two proteins) vaccine candidate consisting of VLPs representing two common genotypes of norovirus and is co-formulated with an aluminum hydroxide (alum) adjuvant, which is commonly used in adult and pediatric vaccines to enhance immunogenicity. HIL-214 comprises VLPs for the two major genotypes of norovirus: GI.1 and GII.4. The firm's clinical development plan is focused on infants.

Contact

MASSACHUSETTS
Boston
75 State St., Suite 100
+16172135054
https://www.hillevax.com/

IPO

2022-04-29

Employees

-

Officers

President, CEO & Chairman of the Board
Dr. Robert M. Hershberg M.D., Ph.D.
Chief Business Officer & Director
Dr. Aditya Kohli Ph.D.
CFO & Treasurer
Mr. Shane A. Maltbie
Chief Operating Officer
Mr. Sean McLoughlin
Chief Technology Officer
Dr. Anju Chatterji Ph.D.
General Counsel, Secretary & Chief Administrative Officer
Mr. Paul S. Bavier J.D.
Show More
Chief Medical Officer
Ms. Astrid Borkowski M.D., Ph.D.
Senior Vice President of Regulatory Affairs
Mr. Ozzie Berger
Show Less

See Also

Discover More